Research guide · Published July 22, 2026 · Sources checked July 22, 2026
SLU-PP-332 and ERR signaling: what “exercise mimetic” means in research
SLU-PP-332 is an experimental small-molecule chemical probe developed as an agonist of estrogen-related receptors (ERRs), with the highest reported potency at ERR-alpha. It is not a peptide and should not be confused with estrogen itself.
Short answer
The phrase ‘exercise mimetic’ summarizes selected transcriptional, mitochondrial, skeletal-muscle, endurance, and metabolic observations in cells and mice. It does not mean SLU-PP-332 reproduces exercise in people, and no cited human trial establishes safety or efficacy.
Evidence boundary: The cited evidence is preclinical and does not establish dosing, safety, efficacy, or replacement of physical exercise in humans. Catalog materials are supplied only for qualified in vitro laboratory research and are not for human or animal use.
Comparison at a glance
| Research dimension | What was studied | What it does not establish |
|---|---|---|
| Primary target class | ERR-alpha, ERR-beta, and ERR-gamma nuclear-receptor activity | Equivalence to estrogen-receptor signaling |
| Discovery models | Receptor assays, C2C12 cells, mouse skeletal muscle, and endurance testing | A human exercise substitute |
| Metabolic-disease models | Mouse energy expenditure, adiposity, and insulin-sensitivity-associated measurements | Clinical treatment effects |
| 2026 optimization work | Structure–activity relationships, transcriptional responses, solubility, and metabolic stability | Approval, human safety, or superiority of an analogue |
How to interpret the comparison
ERRs are transcriptional regulators associated with oxidative metabolism and mitochondrial programs. Activating those receptors in an assay is a molecular observation; the downstream effect depends on tissue, exposure, species, and experimental design.
The term ‘exercise mimetic’ is a research shorthand, not a literal equivalence claim. Exercise produces mechanical, cardiovascular, neural, endocrine, and behavioral effects that are not captured by one receptor-agonist experiment.
Primary sources
- Billon et al., ACS Chemical Biology (2023) — Identification of SLU-PP-332, ERR pharmacology, cellular respiration, skeletal-muscle measurements, and mouse endurance experiments. DOI: 10.1021/acschembio.2c00720
- Huang et al., Journal of Pharmacology and Experimental Therapeutics (2023) — Preclinical metabolic-syndrome experiments examining SLU-PP-332 in mouse models. DOI: 10.1124/jpet.123.001733
- Okda et al., International Journal of Biological Macromolecules (2026) — Structure–activity research on the SLU-PP-332 scaffold, ERR transcriptional activity, and selected physicochemical properties. DOI: 10.1016/j.ijbiomac.2026.151450
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.